Iowa 2023-2024 Regular Session

Iowa House Bill HF2668 Latest Draft

Bill / Enrolled Version Filed 04/16/2024

                            House File 2668 - Enrolled   House File 2668   AN ACT   RELATING TO INSURANCE COVERAGE FOR BIOMARKER TESTING.   BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:    Section 1. NEW SECTION   . 514C.36 Biomarker testing     coverage.    1. As used in this section, unless the context otherwise    requires:    a. Biomarker means a characteristic that is objectively    measured and evaluated as an indicator of normal biological    processes, pathogenic processes, or pharmacologic responses to    a specific therapeutic intervention, including but not limited    to genetic mutations or protein expression.    b. Biomarker testing means the analysis of an individuals    tissue, blood, or other biospecimen for the presence of a    biomarker, including but not limited to single-analyte tests,    multiplex panel tests, or whole genome sequencing.    c. Clinical utility means sufficient medical and    scientific evidence indicating that the use of a biomarker test    will provide meaningful information that affects treatment    decisions and guides improvement of net health outcomes,    including an improved quality of life or longer survival.    d. Consensus statement means a statement developed by    an independent, multidisciplinary panel of experts, none of    whom have a conflict of interest, who utilize a transparent    methodology and reporting structure. A consensus statement    concerns specific clinical circumstances and is based on the    

  House File 2668, p. 2   best available evidence for the purpose of optimizing the    outcomes of clinical care.    e. Covered person means a policyholder, subscriber, or    other person participating in a policy, contract, or plan that    provides for third-party payment or prepayment of health or    medical expenses.    f. Health care professional means the same as defined in    section 514J.102.    g. Local coverage determinations means the same as defined    in section 1869(f)(2)(B) of the federal Social Security Act.    h. National coverage determinations means the same as    defined in section 1869(f)(1)(B) of the federal Social Security    Act.    i. Nationally recognized clinical practice guidelines    means evidence-based clinical practice guidelines developed by    independent organizations or medical professional societies,    none of which have a conflict of interest, that utilize a    transparent methodology and reporting structure. Clinical    practice guidelines establish standards of care informed    by a systematic review of evidence and assessment of the    costs and benefits of alternative care options and include    recommendations intended to optimize patient care.    2. Notwithstanding the uniformity of treatment requirements    of section 514C.6, a policy, contract, or plan providing for    third-party payment or prepayment of medical expenses shall    provide coverage for biomarker testing for the purposes of    diagnosing, treating, appropriately managing, or monitoring a    disease or condition in a covered person when the biomarker    testing has demonstrated clinical utility, including but not    limited to any of the following:    a. Labeled indications for a test approved or cleared by    the United States food and drug administration or indicated    tests for a drug approved by the United States food and drug    administration.      b. Centers for Medicare and Medicaid services of the      United States department of health and human services national    coverage determinations or Medicare administrative contractor    local coverage determinations.    c. Nationally recognized clinical practice guidelines and   

  House File 2668, p. 3   consensus statements.    3. Coverage required under this section shall limit    disruptions in care, including mitigating the need for a    covered person to undergo multiple biopsies or to provide    multiple biospecimen samples.    4. A covered person and the covered persons health care    professional shall have access to a clear and convenient    process available on the health carriers internet site to    request an exception to coverage provided under this section.    5. a. This section applies to the following classes of    third-party payment provider policies, contracts, or plans    delivered, issued for delivery, continued, or renewed in this    state on or after January 1, 2025:    (1) Individual or group accident and sickness insurance    providing coverage on an expense-incurred basis.    (2) An individual or group hospital or medical service    contract issued pursuant to chapter 509, 514, or 514A.    (3) An individual or group health maintenance organization    contract regulated under chapter 514B.    (4) A plan established pursuant to chapter 509A for public    employees.    b. This section shall apply to all of the following:    (1) The medical assistance program under chapter 249A.    (2) The healthy and well kids in Iowa (Hawki) program under    chapter 514I.    (3) A managed care organization acting pursuant to a    contract with the department of health and human services under    chapter 249A, or with the healthy and well kids in Iowa (Hawki)    program under chapter 514I.    c. This section shall not apply to accident-only,    specified disease, short-term hospital or medical, hospital    confinement indemnity, credit, dental, vision, Medicare    supplement, long-term care, basic hospital and medical-surgical    expense coverage as defined by the commissioner, disability    income insurance coverage, coverage issued as a supplement    to liability insurance, workers compensation or similar    insurance, or automobile medical payment insurance.    6. The commissioner of insurance may adopt rules pursuant to    chapter 17A to administer this section.   

  House File 2668, p. 4   Sec. 2. DEPARTMENT OF HEALTH AND HUMAN SERVICES  REQUIRED    REPORT. Before November 1, 2025, the department of health    and human services shall report the number of biomarker tests    provided during fiscal year 2025, and the resulting cost of    providing the biomarker tests during fiscal year 2025, to    individuals pursuant to this Act that are covered by the    medical assistance program under chapter 249A and the healthy    and well kids in Iowa (Hawki) program under chapter 514I.    ______________________________   PAT GRASSLEY   Speaker of the House   ______________________________   AMY SINCLAIR   President of the Senate   I hereby certify that this bill originated in the House and   is known as House File 2668, Ninetieth General Assembly.   ______________________________   MEGHAN NELSON   Chief Clerk of the House   Approved _______________, 2024 ______________________________   KIM REYNOLDS   Governor